Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).

Trial Details

NCT ID
NCT07463599
Phase
PHASE1 / PHASE2
Sponsor
HonorHealth Research Institute
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Tegavivint
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903

Key Eligibility Criteria

  • Signed informed consent form (ICF)
  • Male or female, 18 years of age or older
  • Histologically and/or cytologically documented metastatic colorectal adenocarcinoma (all other histological types are excluded)
  • a. RAS, BRAF, and MSI/ dMMR (Mismatch repair deficiency) status for each patient must be documented.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →